CG
RCUS icon

Cutler Group’s Arcus Biosciences RCUS Stock Holding History

Cutler Group’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,000
Closed -$9K – 3333
2023
Q4 		$9K Buy
+2,000
New +$32K ﹤0.01% 2472
2022
Q4 		– Sell
-2,200
Closed -$3K – 5059
2022
Q3 		$3K Buy
+2,200
New +$58.2K ﹤0.01% 4019
2022
Q2 		– Sell
-1,800
Closed -$4K – 5537
2022
Q1 		$4K Buy
1,800
+800
+80% +$26.8K ﹤0.01% 4315
2021
Q4 		$3K Buy
+1,000
New +$38.8K ﹤0.01% 4562

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Cutler Group's RCUS Position: Q3 2023 in Review

Cutler Group sold out of Arcus Biosciences (RCUS) in Q3 2023, closing a stake of 1,200 shares — an estimated $24.1K sold.

Cutler Group first reported a position in RCUS in Q1 2020 and held it in 12 quarters. The position peaked at $132K in Q2 2022. 187 funds tracked by Wall St. Rank hold RCUS as of Q3 2023.

  • Cutler Group reported no remaining Arcus Biosciences position as of Q3 2023 after selling out during the quarter.
  • Cutler Group sold 1,200 Arcus Biosciences shares in Q3 2023, an estimated $24.1K.
  • Cutler Group first reported a position in Arcus Biosciences in Q1 2020 and held it in 12 quarters.
  • Cutler Group's Arcus Biosciences position peaked at $132K in Q2 2022.
  • 187 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2023.

Based on Cutler Group's 13F filing for Q3 2023, filed 7 Nov 2023.